13:37:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-14 Bokslutskommuniké 2024
2024-10-30 Kvartalsrapport 2024-Q3
2024-07-10 Kvartalsrapport 2024-Q2
2024-05-23 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-07 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-06-21 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2023-06-20 Årsstämma 2023
2023-05-10 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-09 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-12 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2022-05-11 Kvartalsrapport 2022-Q1
2022-05-11 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-07 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2021-05-06 Kvartalsrapport 2021-Q1
2021-05-06 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-08 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2020-05-07 Kvartalsrapport 2020-Q1
2020-05-07 Årsstämma 2020
2020-02-06 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-28 Split IRLAB A 1:5
2019-04-26 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2019-04-25 Kvartalsrapport 2019-Q1
2019-04-25 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-17 X-dag ordinarie utdelning IRLAB A 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-16 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-27 Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
IRLAB Therapeutics är ett svenskt forsknings- och läkemedelsbolag. Forskningen utgår ifrån bolagets egna forskningsplattform och är specialiserad mot behandling av hjärnsjukdomar, vanligen benämnt neurodegenerativa sjukdomar. I nuvarande stund har bolaget läkemedelskandidater specialiserade mot bland annat Parkinsons sjukdom. Huvudkontoret ligger i Göteborg.
2024-05-23 12:30:00

Gothenburg, Sweden, May 23, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, announces today that the company has made a drawdown of SEK 25 million within the framework of a loan facility totaling SEK 55 million that was issued by Fenja Capital, previously Formue Nord, in December 2023. The amount constitutes the second and final tranche of the loan facility, which has thus now been utilized in full.

RLAB has a world-leading portfolio of drug candidates aiming to transform the lives of people living with Parkinson’s disease and other neurological diseases. The portfolio, including five drug candidates of which three are in the clinical phase, has recently continued to develop extremely well. The cash injection increases IRLAB's ability to strengthen the company's development projects and ongoing business development activities to facilitate attractive agreements with licensees, partners and other collaborators for the drug candidates in the portfolio.

“After recently securing full funding for one of our clinical drug candidates, IRL757, all the way through clinical Proof-of-Concept through a development agreement with MSRD/Otsuka, we are now strengthening our resources for our other development projects by utilizing the last tranche of the loan agreement with Fenja Capital. A strong financial position is important to be able to achieve the value-creating milestones in our portfolio that we expect over the next 12–18 months," says Viktor Siewertz, Chief Financial Officer, IRLAB.

Loan terms
The loan amounts to a total of up to SEK 55 million and is divided into two tranches. The first tranche of SEK 30 million was paid out upon signing of the loan agreement in December 2023, and the second tranche, SEK 25 million, was drawn today, May 23, 2024. The loan matures for payment on May 22, 2025. The lender has the right to convert SEK 10 million of the loan to shares at a share price corresponding to 130 per cent of the volume-weighted average price during 10 trading days preceding the date of signing of the loan agreement. In addition to a set-up fee amounting to 5 percent of the loan facility, the loan carries an annual interest rate of STIBOR 3M + 10 percent of the outstanding loan amount and will be paid at the end of each calendar quarter. IRLAB has the right to repay the loan at any time without any redemption fee. The Board and company have assessed the loan terms as market competitive and consider taking the loan to be in the best interest of both the company and its shareholders.